Karyopharm Therapeutics operates within the healthcare sector, specifically focusing on the biotechnology and commercial-stage biopharmaceutical industry. The company pioneers novel cancer therapies and targeted treatments designed to alter nuclear transport mechanisms and address severe hematologic malignancies and solid tumors, striving to fulfill critical unmet medical needs for oncology patients worldwide through intensive scientific research and clinical trial execution.